Navigation Links
InDex Pharmaceuticals Gets Patent for Additional DIMS Compounds Granted in the US
Date:3/14/2017

STOCKHOLM, March 14, 2017 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced that a patent covering 19 compounds from the company's DIMS platform has been granted by the United States Patent and Trademark Office (USPTO).

InDex has a discovery stage portfolio of more than 150 DNA-based ImmunoModulatory Sequences (DIMS), several of which are already protected by approved composition-of-matter patents. The new US patent, entitled Methods for identifying biologically active oligonucleotides capable of modulating the immune system (patent number 9593337), covers both the composition-of-matter and method-of-use of 19 different DIMS compounds for the treatment of inflammatory diseases, cancer and infectious diseases. The patent was filed in 2011 and provides an exclusivity period until December 2031, with the possibility of up to 5 years term extension after market approval.

"We continue the work to broaden our preclinical DIMS portfolio in parallel with the clinical development of our lead drug candidate cobitolimod," said Peter Zerhouni, CEO of InDex Pharmaceuticals. "This new patent further strengthens our robust intellectual property portfolio and we are very pleased that the USPTO confirms the novelty of our DIMS platform."

InDex's DIMS compunds are synthetic oligonucleotides that function as immunomodulatory agents by targeting Toll-like receptor 9 (TLR9). DIMS mimic bacterial DNA, without being harmful, and stimulate immune cells to produce beneficial anti-inflammatory cytokines that help to dampen inflammation. This opens up opportunities for the treatment of different inflammatory conditions, in which the immune responses are imbalanced. The company's foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis. Besides cobitolimod there are other DIMS candidates that the Company has selected for further preclinical development. InDex has been awarded a grant of SEK 1.8 million for this development from the Swedish innovation agency Vinnova.

For more information:
Peter Zerhouni, CEO
Phone: +46-8-508-847-35
E-mail: peter.zerhouni@indexpharma.com 

InDex Pharmaceuticals in brief
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company's foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis - a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.

InDex is based in Stockholm, Sweden. The company's shares are traded on Nasdaq First North Stockholm. Redeye AB is the company's Certified Adviser. For more information, please visit www.indexpharma.com

Publication
This information is information that InDex Pharmaceuticals Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication through the agency of the contact person set out above at 8:00 CET on March 14, 2017.

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/index-pharmaceuticals/r/index-pharmaceuticals-gets-patent-for-additional-dims-compounds-granted-in-the-us,c2211345

The following files are available for download:

http://mb.cision.com/Main/9612/2211345/641834.pdf

PDF

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/index-pharmaceuticals-gets-patent-for-additional-dims-compounds-granted-in-the-us-300423152.html


'/>"/>
SOURCE Index Pharmaceuticals
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. New Access to Vaccines Index Reveals First Landscape of Vaccine Company Actions to Improve Immunisation Coverage
2. InDex Pharmaceuticals Holding AB (publ) Year end Report 2016
3. InDex Pharmaceuticals Enters Agreement With CRO for the CONDUCT Study
4. InDex Pharmaceuticals Will Participate in the European Crohns and Colitis Organisation (ECCO) Congress
5. Cal INDEX and Inland Empire HIE will merge to form Californias largest health information exchange; former White House technology advisor named CEO
6. Aralez Added To The NASDAQ Biotechnology Index
7. Mallinckrodt Pharmaceuticals Earns Top Marks In 2017 Corporate Equality Index
8. CVS Health Achieves 100 Percent on 2017 Corporate Equality Index for Third Consecutive Year
9. Pulmatrix Added to Russell Microcap Index
10. Confidence Wanes as Uncertainty Builds in the Q4 2015 Biopharma CEO Confidence Index
11. Blueprint Medicines Added to NASDAQ Biotechnology Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2018)... ... August 11, 2018 , ... Award-winning actor and philanthropist Laurence ... medicine. The episode will go through different integrative medicine options and how they ... using both conventional and complementary approaches to health care in a coordinated way. ...
(Date:8/7/2018)... ... August 06, 2018 , ... Drs. Jonathan ... Clinton, MS using laser dentistry techniques. Using their BIOLASE WaterLase® dental laser, this ... called REPAIR Perio™. , Affecting the lives of millions of Americans, gum disease ...
(Date:8/7/2018)... ... August 07, 2018 , ... ... Morehouse, DO, to its growing team of eye care providers. Dr. Morehouse performs ... traditional intraocular lenses, as well as treating patients for routine eye care, glaucoma, ...
Breaking Medicine Technology:
(Date:8/3/2018)... (PRWEB) , ... August 03, 2018 , ... Yisrayl Hawkins, ... week that reveals secret passages and meanings from the Bible meant only to be ... Bible Prophecy and he has been able to decode passages that he says scholars ...
(Date:8/2/2018)... ... , ... Dr. Srini Pillay , best-selling author of TINKER DABBLE ... care less, demonstrating a “whatever” attitude toward life, people, and situations around them. , ... overlooked reason relates to being overworked. Called self-regulation depletion (SRD), this condition occurs when ...
(Date:8/2/2018)... ... August 02, 2018 , ... Mindray, ... 7 Ultrasound system with unique new upgrades at the Society of Vascular Ultrasound ... ZONE Sonography® Technology (ZST), the upgrades include a unique arterial stiffness measurement, which ...
(Date:8/2/2018)... ... 02, 2018 , ... Training Industry, Inc. named The ... of 2018 . The selection recognizes TGA’s award-winning, game-based solutions that are transforming ... game-based tools they need to be successful, and in so doing, help their ...
(Date:8/2/2018)... ... August 02, 2018 , ... ... management solutions provider, announced today that it has acquired Minneapolis, Minnesota-based Integrity ... record reviews, peer reviews, and related services. , Medlogix seeks to deliver ...
Breaking Medicine News(10 mins):